eFinder

eFinder

Home › Stock Market Impact › Article

Regeneron drops after skin cancer treatment misses late-stage trial goal

Cnbc · · 155 words · By WATCH LIVE
Stock Market Impact Pharmaceutical Trial Results
open_in_new Read the original article: https://www.cnbc.com/2026/05/18/regeneron-drops-after-skin-cancer-treatment-miss…

psychologyDetected Techniques

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.

fact_checkFact-Check Results

7 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

verified Verified 3
check_circle Corroborated 2
info Single Source 1
verified Verified By Reference 1
info
“Shares of Regeneron fell 11.8% premarket on Monday”
SINGLE SOURCE
The provided evidence mentions Regeneron shares falling to $568 in pre-market trading on a Tuesday (BioSpace) and rising 1.4% on a Wednesday (MarketWatch), but none of the sources confirm a specific 11.8% drop on a Monday.
travel_explore
web search NEUTRAL — According to BMO Capital Markets, Regeneron’s earnings missed on top and bottom line. The company reported first quarter earnings of $3 billion.Regeneron’s shares fell to $568 in pre-market trading on…
https://www.biospace.com/business/regeneron-shares-tumble-as…
travel_explore
web search NEUTRAL — Regeneron Pharmaceuticals Inc. shares rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter.
https://www.marketwatch.com/story/regeneron-shares-up-14-pre…
travel_explore
web search NEUTRAL — View pre-market trading, including futures information for the S&P 500, Nasdaq Composite and Dow Jones Industrial Average.
https://www.cnn.com/markets/premarkets
check_circle
“the company's experimental treatment missed the main goal in a late-stage trial in patients with advanced melanoma”
CORROBORATED
Multiple independent sources confirm that Regeneron's fianlimab combination missed its primary endpoint in a melanoma trial.
travel_explore
web search NEUTRAL — Regeneron’s Fianlimab Misses Primary Endpoint in Melanoma Trial. 18 hours ago. By Jon Napitupulu. Save for later.Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma. Ye…
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
travel_explore
web search NEUTRAL — The study met its primary endpoint, showing substantially lower rates of grade 3 or 4 treatment-related adverse events at six months in the intratumoral group compared with the intravenous group, 22.6…
https://www.managedhealthcareexecutive.com/view/injecting-im…
travel_explore
web search NEUTRAL — melanoma met its primary endpoint with a statistically significant improvement in PFS observed vs investigator’s choice of therapy.
https://www.linkedin.com/posts/longitude-capital_longitude-p…
verified
“The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS)”
VERIFIED
Regeneron's own update explicitly states that the trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab.
travel_explore
web search NEUTRAL — The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy. No new safety signal…
https://www.barchart.com/story/news/1968125/regeneron-provid…
travel_explore
web search NEUTRAL — If fianlimab plus cemiplimab cannot beat that benchmark against a LAG-3 combination rather than a PD-1 monotherapy, the program’s first-line melanoma ambitions are effectively finished — regardless of…
https://www.clinicaltrialvanguard.com/news/regenerons-fianli…
travel_explore
web search NEUTRAL — An investigational combination of fianlimab, a LAG-3 inhibitor, and cemiplimab (Libtayo; Regeneron Pharmaceuticals, Inc), a PD-1 inhibitor, showed positive data in a phase 1 trial among patients with …
https://www.pharmacytimes.com/view/study-fianlimab-with-cemi…
verified
“Advanced melanoma is a serious form of skin cancer that can spread rapidly to other parts of the body”
VERIFIED BY REFERENCE
Authoritative medical sources (American Cancer Society, U.S. News) confirm that melanoma is an aggressive skin cancer that can metastasize to other parts of the body.
travel_explore
web search NEUTRAL — Melanoma, a type of skin cancer, is very aggressive. It grows fast and can spread to other parts of the body.Metastasis is when cancer cells spread to other parts of the body. In melanoma, this often …
https://int.livhospital.com/what-is-skin-cancers-manner-of-d…
travel_explore
web search NEUTRAL — Learn the essential facts about skin cancer, including the three main types (basal cell, squamous cell and melanoma), key symptoms, major risk factors and current treatment options like surgery and im…
https://health.usnews.com/conditions/cancer/skin-cancer
travel_explore
web search NEUTRAL — Melanoma skin cancers. Other types of skin cancer. Benign skin tumors.These cancers (especially BCCs) are much less likely to spread (metastasize) to other parts of the body than are melanomas, so the…
https://www.cancer.org/cancer/types/melanoma-skin-cancer/abo…
check_circle
“The study tested fianlimab and Regeneron's approved drug cemiplimab, sold under the brand name Libtayo, as a first-line treatment”
CORROBORATED
Multiple sources confirm the study tested the combination of fianlimab and cemiplimab (Libtayo) as a first-line treatment for advanced melanoma, comparing it against Keytruda.
travel_explore
web search NEUTRAL — The combination of fianlimab and cemiplimab (Libtayo) demonstrated efficacy and safety in patients with advanced melanoma including some who had previously received adjuvant immunotherapy for advanced…
https://www.targetedonc.com/view/fianlimab-plus-cemiplimab-s…
travel_explore
web search NEUTRAL — Regeneron’s anti-Lag3 antibody fianlimab faces a pivotal 2024, with results of its phase 3 study in first-line melanoma, pitting a Libtayo combo against Merck & Co’s Keytruda, due to yield data in the…
https://www.oncologypipeline.com/apexonco/regeneron-works-se…
travel_explore
web search NEUTRAL — Clinical study of fianlimab in combination with cemiplimab in adolescent and adult patients with previously untreated unresectable locally advanced or metastatic melanoma. ClinicalTrials.gov.
https://www.onclive.com/view/fianlimab-plus-cemiplimab-gener…
verified
“The combination treatment showed a numeric improvement of 5.1 months in median PFS when compared with Merck's Keytruda”
VERIFIED
Regeneron's official update explicitly mentions a numeric improvement of 5.1 months in median PFS for the high-dose fianlimab combination compared to pembrolizumab (Keytruda).
travel_explore
web search NEUTRAL — A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy.Primary endpoint: median PFS, months (95% Confidence Interv…
https://www.barchart.com/story/news/1968125/regeneron-provid…
travel_explore
web search NEUTRAL — In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma…
https://www.targetedonc.com/view/fianlimab-plus-cemiplimab-s…
travel_explore
web search NEUTRAL — Show more results ->. Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations.
https://www.nasdaq.com/press-release/fianlimab-lag-3-inhibit…
verified
“the difference did not reach statistical significance”
VERIFIED
Regeneron's official update confirms that while there was a numeric improvement, the trial 'did not reach statistical significance' for the primary endpoint of PFS.
travel_explore
web search NEUTRAL — The evolution of the modern Western digit for the numeral for five is traced back to the Indian system of numerals, where on some earlier versions, the numeral bore resemblance to variations of the nu…
https://en.wikipedia.org/wiki/5
travel_explore
web search NEUTRAL — Mar 11, 2024 · Curious about some unique facts about the number 5? Dive into an array of characteristics, from its prime status to its role in nature, language, and sports!
https://kidadl.com/facts/math-science/facts-about-the-number…
travel_explore
web search NEUTRAL — Apr 20, 2026 · The number five holds significant symbolic meaning across various cultures and belief systems. It is often seen as representing human life and marriage, stemming from the Pythagorean co…
https://www.britannica.com/science/the-number-five
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.